E. M. Goncharova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
E. M. Goncharova has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Marina Arkadievna Kinkulkina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
5 shared publications - Nikolay Nikolaevich Ivanets
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
5 shared publications - Aleksandr E. Morozov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4 shared publications - Beatrisa Albertovna Volel
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4 shared publications - D. A. Golovkina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4 shared publications - Evgeny Nikolaevich Morozov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 58-65
Safety and tolerability of Aviandr (maritupirdine) in long-term therapy of generalized anxiety disorder: results of a 36-week post-marketing observational study
Long-term therapy is necessary for the prevention of relapses of generalized anxiety disorder (GAD), and adherence to it may be hindered by the development of adverse events (AEs). The new domestic drug Aviandr (maritupirdine) has shown efficacy and good tolerability in the treatment of GAD in clinical trials. Objective: to evaluate the safety and tolerability profile of long-term (36-week) GAD therapy with Aviandr (maritupirdine) in real-world clinical practice. Material and methods. An open-label, non-comparative prospective study included 126 patients over 18 years of age with an established diagnosis of GAD. The frequency and severity of AEs, the dynamics of daytime sleepiness on a visual analogue scale (VAS), the presence of with-drawal syndrome, and tolerability features in special patient groups (elderly individuals, patients with somatic comorbidity) were assessed. Results. The vast majority of patients (98.4%) completed the 36-week course of therapy; no patient discontinued the drug due to AEs. Drug-related AEs were registered in 13.49% of patients, predominantly mild in severity (73.1%). The most common AE was somnolence (5.56%), but no clinically significant sedation was noted: the VAS daytime sleepiness score decreased significantly from 39.72±26.29 to 17.73±17.23 by week 36 (pConclusion. Aviandr demonstrates a high safety and tolerability profile in long-term GAD therapy. The absence of sedation, worsening of anxiety, sexual dysfunction, and withdrawal syndrome ensures high adherence to treatment and makes the drug a safe agent of choice for elderly patients and individuals with concomitant somatic pathology.
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 58-65
Open AccessSafety and tolerability of Aviandr (maritupirdine) in long-term therapy of generalized anxiety disorder: results of a 36-week post-marketing observational study
Long-term therapy is necessary for the prevention of relapses of generalized anxiety disorder (GAD), and adherence to it may be hindered by the development of adverse events (AEs). The new domestic drug Aviandr (maritupirdine) has shown efficacy and good tolerability in the treatment of GAD in clinical trials. Objective: to evaluate the safety and tolerability profile of long-term (36-week) GAD therapy with Aviandr (maritupirdine) in real-world clinical practice. Material and methods. An open-label, non-comparative prospective study included 126 patients over 18 years of age with an established diagnosis of GAD. The frequency and severity of AEs, the dynamics of daytime sleepiness on a visual analogue scale (VAS), the presence of with-drawal syndrome, and tolerability features in special patient groups (elderly individuals, patients with somatic comorbidity) were assessed. Results. The vast majority of patients (98.4%) completed the 36-week course of therapy; no patient discontinued the drug due to AEs. Drug-related AEs were registered in 13.49% of patients, predominantly mild in severity (73.1%). The most common AE was somnolence (5.56%), but no clinically significant sedation was noted: the VAS daytime sleepiness score decreased significantly from 39.72±26.29 to 17.73±17.23 by week 36 (pConclusion. Aviandr demonstrates a high safety and tolerability profile in long-term GAD therapy. The absence of sedation, worsening of anxiety, sexual dysfunction, and withdrawal syndrome ensures high adherence to treatment and makes the drug a safe agent of choice for elderly patients and individuals with concomitant somatic pathology.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 161-171
Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study
Objective. To evaluate the efficacy and safety of non-benzodiazepine anxiolytic maritupirdine (Aviandr) in patients with panic disorder. Material and methods. In a multicenter, randomized, double-blind, placebo-controlled study with an open-label comparison, 288 patients with moderate PD were assigned to receive Aviandr 40 mg/day (n=144), placebo (n=72), or paroxetine 40 mg/day (n=72). The treatment duration was 12 weeks. Clinical and psychopathological, psychometric methods and statistical analysis were used. The Panic Disorder Severity Scale (PDSS), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), the Clinical Global Impression Scale (CGI), the Visual Analog Scale (VAS) of daytime sleepiness and the Sheehan Disability Scale (SDS) were used for a standardized assessment of the state change. The primary endpoint was the change in Panic Disorder Severity Scale (PDSS) total score at week 12. Results. The PDSS score reduction in the Aviandr group (–4.99) was statistically and clinically significantly greater than in the placebo group (–2.28; p=0.047). The drug demonstrated a rapid onset of action, with significant improvement beginning at week 2. Aviandr’s efficacy on secondary endpoints (SIGH-A and CGI) was also superior to placebo. The need for symptomatic hydroxyzine therapy was significantly lower in the Aviandr group. The safety profile was favorable, with adverse event rates comparable to placebo (44.44%) and lower than in the paroxetine group (50%). No serious adverse events were recorded. Conclusion. Aviandr demonstrated statistically significant superiority over placebo, rapid onset of action, and a favorable safety profile, making it a promising treatment option for panic disorder.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 161-171
Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study
Objective. To evaluate the efficacy and safety of non-benzodiazepine anxiolytic maritupirdine (Aviandr) in patients with panic disorder. Material and methods. In a multicenter, randomized, double-blind, placebo-controlled study with an open-label comparison, 288 patients with moderate PD were assigned to receive Aviandr 40 mg/day (n=144), placebo (n=72), or paroxetine 40 mg/day (n=72). The treatment duration was 12 weeks. Clinical and psychopathological, psychometric methods and statistical analysis were used. The Panic Disorder Severity Scale (PDSS), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), the Clinical Global Impression Scale (CGI), the Visual Analog Scale (VAS) of daytime sleepiness and the Sheehan Disability Scale (SDS) were used for a standardized assessment of the state change. The primary endpoint was the change in Panic Disorder Severity Scale (PDSS) total score at week 12. Results. The PDSS score reduction in the Aviandr group (–4.99) was statistically and clinically significantly greater than in the placebo group (–2.28; p=0.047). The drug demonstrated a rapid onset of action, with significant improvement beginning at week 2. Aviandr’s efficacy on secondary endpoints (SIGH-A and CGI) was also superior to placebo. The need for symptomatic hydroxyzine therapy was significantly lower in the Aviandr group. The safety profile was favorable, with adverse event rates comparable to placebo (44.44%) and lower than in the paroxetine group (50%). No serious adverse events were recorded. Conclusion. Aviandr demonstrated statistically significant superiority over placebo, rapid onset of action, and a favorable safety profile, making it a promising treatment option for panic disorder.
- 20 December 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (6)
Long-term treatment of generalised anxiety disorder with Aviandr: results of a 36-week post-registration observational study
The management of patients with generalised anxiety disorder (GAD) is a pressing issue in modern medicine. A new Russian drug, Aviandr (maritupridine), has demonstrated efficacy and good tolerability in the treatment of GAD in clinical trials. Objective : To study the effectiveness of treating GAD with Aviandr in real clinical practice. Material and methods . An open-label, non-comparative prospective study included 98 patients over the age of 18 with a confirmed diagnosis of GAD. Patients received Aviandr therapy and were monitored on an outpatient basis for 36 weeks. Clinical-psychopathological and psychometric examinations were conducted before treatment and at 2, 8, 16, 24, and 36 weeks after the start of treatment. Anxiety symptoms were measured using the Hamilton Anxiety Rating Scale (structured interview, SIGH-A). Additionally, symptoms of depression (Montgomery-Asberg Depression Rating Scale – MADRS), cognitive functions (Montreal Cognitive Assessment Scale – MoCA), and the somatic condition of patients were assessed. Results. Aviandr has proven to be an effective drug for treating GAD. A statistically significant reduction in the total SIGH-A score was observed as early as the second week of therapy (from 22.06±5.80 before therapy to 19.12±5.91; pConclusion . The use of Aviandr is an effective method of treating GAD. The therapeutic effect of the drug manifested itself gradually, demonstrating a progressive increase throughout the course of therapy, with maximum symptom reduction achieved by the 36th week of treatment.
- 20 December 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (6)
Long-term treatment of generalised anxiety disorder with Aviandr: results of a 36-week post-registration observational study
The management of patients with generalised anxiety disorder (GAD) is a pressing issue in modern medicine. A new Russian drug, Aviandr (maritupridine), has demonstrated efficacy and good tolerability in the treatment of GAD in clinical trials. Objective : To study the effectiveness of treating GAD with Aviandr in real clinical practice. Material and methods . An open-label, non-comparative prospective study included 98 patients over the age of 18 with a confirmed diagnosis of GAD. Patients received Aviandr therapy and were monitored on an outpatient basis for 36 weeks. Clinical-psychopathological and psychometric examinations were conducted before treatment and at 2, 8, 16, 24, and 36 weeks after the start of treatment. Anxiety symptoms were measured using the Hamilton Anxiety Rating Scale (structured interview, SIGH-A). Additionally, symptoms of depression (Montgomery-Asberg Depression Rating Scale – MADRS), cognitive functions (Montreal Cognitive Assessment Scale – MoCA), and the somatic condition of patients were assessed. Results. Aviandr has proven to be an effective drug for treating GAD. A statistically significant reduction in the total SIGH-A score was observed as early as the second week of therapy (from 22.06±5.80 before therapy to 19.12±5.91; pConclusion . The use of Aviandr is an effective method of treating GAD. The therapeutic effect of the drug manifested itself gradually, demonstrating a progressive increase throughout the course of therapy, with maximum symptom reduction achieved by the 36th week of treatment.
- 15 January 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 104-116
Efficacy and safety of Aviandr in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study
Prevalence of anxiety disorders has increased in last decades, specifically in COVID-19 pandemic. Despite the frequency and burden of post-COVID anxiety disorders, there are still no recommendations for the treatment of these conditions. The article presents the interim results of a post-registration multicenter observational study of the efficacy and safety of a new original drug Aviandr in the treatment of anxiety developing after COVID-19. The study included 170 patients over 18 years of age treated by Aviandr for 6 weeks at a dose of 20 mg 2 times a day. All patients completed 6 weeks of treatment and 2 weeks of follow-up. The decrease in the average total score of the Hamilton Rating Scale for Anxiety (SIGH-A) was 77.13 % of the baseline values. Most patients experienced clinical improvement; 72.35 % patients have reached remission by week 6 of therapy. The drug was equally effective in different age groups (≤/> 65 years). It is important to note that Aviandr was effective in relieving both mental and somatic anxiety, measured with SIGH-A scale — the reduction in average scores was 75.13 % and 79.12 %, respectively. The study drug showed a good safety profile. Adverse events were observed in 5.88 % of patients; 85.7 % of AEs were mild, only 14.3 % were moderate. Thus, Aviandr showed good efficacy in the treatment of anxiety disorders after COVID-19. The absence of withdrawal syndrome, drug dependence, a high safety profile, including in elderly patients, make Aviandr a good choice for use in clinical practice.
- 15 January 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 104-116
Efficacy and safety of Aviandr in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study
Prevalence of anxiety disorders has increased in last decades, specifically in COVID-19 pandemic. Despite the frequency and burden of post-COVID anxiety disorders, there are still no recommendations for the treatment of these conditions. The article presents the interim results of a post-registration multicenter observational study of the efficacy and safety of a new original drug Aviandr in the treatment of anxiety developing after COVID-19. The study included 170 patients over 18 years of age treated by Aviandr for 6 weeks at a dose of 20 mg 2 times a day. All patients completed 6 weeks of treatment and 2 weeks of follow-up. The decrease in the average total score of the Hamilton Rating Scale for Anxiety (SIGH-A) was 77.13 % of the baseline values. Most patients experienced clinical improvement; 72.35 % patients have reached remission by week 6 of therapy. The drug was equally effective in different age groups (≤/> 65 years). It is important to note that Aviandr was effective in relieving both mental and somatic anxiety, measured with SIGH-A scale — the reduction in average scores was 75.13 % and 79.12 %, respectively. The study drug showed a good safety profile. Adverse events were observed in 5.88 % of patients; 85.7 % of AEs were mild, only 14.3 % were moderate. Thus, Aviandr showed good efficacy in the treatment of anxiety disorders after COVID-19. The absence of withdrawal syndrome, drug dependence, a high safety profile, including in elderly patients, make Aviandr a good choice for use in clinical practice.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (1) , 91-97
Psychopharmacotherapy of late-stage hypochondriac conditions: frequency of use and effectiveness of drugs
ЦЕЛЬ ИССЛЕДОВАНИЯ Провести сравнительный анализ эффективности психофармакотерапии ипохондрических расстройств в позднем возрасте и выделить оптимальные сочетания препаратов в зависимости от тимопатического (гипотимического и/или тревожного) компонента, сопровождающего основное ипохондрическое проявление. МАТЕРИАЛ И МЕТОДЫ В исследование были включены 108 пациентов женского пола в возрасте от 50 до 88 лет, проходивших стационарное лечение, с ведущей ипохондрической симптоматикой небредового уровня. Все пациенты обследовались клинико-психопатологически с применением психометрических шкал: шкалы Монтгомери—Асберг, шкалы Гамильтона, шкалы оценки ипохондрии, шкалы нежелательных явлений лекарственной терапии. РЕЗУЛЬТАТЫ На основании психометрической оценки пациенты разделены на следующие группы: 1-я группа — исследуемые с ипохондрической симптоматикой без выраженного тимопатического компонента (n=18); 2-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем гипотимии (n=49); 3-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем тревоги (n=22); 4-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем как тревоги, так и гипотимии (n=19). Ипохондрическое расстройство без тимопатического компонента купировалось монотерапией антипсихотическими препаратами в низких терапевтических дозах или сочетанием антипсихотических препаратов в низких терапевтических дозах с трициклическими антидепрессантами в низких и средних дозах. Гипотимические ипохондрические расстройства купировались антидепрессантами преимущественно СИОЗС и трициклической структуры в сочетании с типичными и атипичными антипсихотическими препаратами в низких терапевтических дозах, в то время как монотерапия антидепрессантами или сочетанием антидепрессантов разных механизмов действия была эффективна лишь в единичных случаях. Ипохондрическое расстройство с выраженным тревожным компонентом достоверно чаще купировалось комплексной терапией с добавлением анксиолитических препаратов, а также комбинацией антидепрессантов с антиптихотическими препаратами, смешанные ипохондрические состояния — сочетанием антидепрессантов с антипсихотическими препаратами или комплексной терапией с добавлением анксиолитического препарата. ЗАКЛЮЧЕНИЕ Ипохондрические расстройства позднего возраста в большинстве случаев сопровождаются депрессивной и/или тревожной симптоматикой, которую необходимо учитывать для повышения эффективности диагностики и своевременного подбора терапии.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (1) , 91-97
Psychopharmacotherapy of late-stage hypochondriac conditions: frequency of use and effectiveness of drugs
ЦЕЛЬ ИССЛЕДОВАНИЯ Провести сравнительный анализ эффективности психофармакотерапии ипохондрических расстройств в позднем возрасте и выделить оптимальные сочетания препаратов в зависимости от тимопатического (гипотимического и/или тревожного) компонента, сопровождающего основное ипохондрическое проявление. МАТЕРИАЛ И МЕТОДЫ В исследование были включены 108 пациентов женского пола в возрасте от 50 до 88 лет, проходивших стационарное лечение, с ведущей ипохондрической симптоматикой небредового уровня. Все пациенты обследовались клинико-психопатологически с применением психометрических шкал: шкалы Монтгомери—Асберг, шкалы Гамильтона, шкалы оценки ипохондрии, шкалы нежелательных явлений лекарственной терапии. РЕЗУЛЬТАТЫ На основании психометрической оценки пациенты разделены на следующие группы: 1-я группа — исследуемые с ипохондрической симптоматикой без выраженного тимопатического компонента (n=18); 2-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем гипотимии (n=49); 3-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем тревоги (n=22); 4-я группа — исследуемые, ипохондрическая концепция которых сочеталась с высоким уровнем как тревоги, так и гипотимии (n=19). Ипохондрическое расстройство без тимопатического компонента купировалось монотерапией антипсихотическими препаратами в низких терапевтических дозах или сочетанием антипсихотических препаратов в низких терапевтических дозах с трициклическими антидепрессантами в низких и средних дозах. Гипотимические ипохондрические расстройства купировались антидепрессантами преимущественно СИОЗС и трициклической структуры в сочетании с типичными и атипичными антипсихотическими препаратами в низких терапевтических дозах, в то время как монотерапия антидепрессантами или сочетанием антидепрессантов разных механизмов действия была эффективна лишь в единичных случаях. Ипохондрическое расстройство с выраженным тревожным компонентом достоверно чаще купировалось комплексной терапией с добавлением анксиолитических препаратов, а также комбинацией антидепрессантов с антиптихотическими препаратами, смешанные ипохондрические состояния — сочетанием антидепрессантов с антипсихотическими препаратами или комплексной терапией с добавлением анксиолитического препарата. ЗАКЛЮЧЕНИЕ Ипохондрические расстройства позднего возраста в большинстве случаев сопровождаются депрессивной и/или тревожной симптоматикой, которую необходимо учитывать для повышения эффективности диагностики и своевременного подбора терапии.
- Open Access
- 1 November 2019
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 11 (3) , 83-88
Nonsuicidal self-injury in mentally ill patients: a clinical case
Nonsuicidal self-injuries (autotomy, self-inflicted destruction, self-mutilation) is a variant of autoaggression in a patient without the intent to take his/her own life. Patients with the consequences of self-injuries receive help from physicians of various specialties, who often cannot determine their motivation for autoaggressive actions, since it is associated with mental disorders. The paper presents data on phenomenology, some classifications and motivation of nonsuicidal self-injuries. Various mental disorders are noted to be the most common cause of autoaggressive behavior. The paper describes a clinical case of a female patient who has mutilated her face for a long time, hiding the cause of her autoaggressive action. A detailed clinical and psychopathological analysis of her medical history and mental status allowed for classifying hypochondriacal delirium within schizophrenia as a cause of self-mutilating actions. The motivation for this behavior was to fight against a pseudotumor, for which the patient suffered pain and prolonged suppurative processes on the skin of the face, without visiting physicians.
- 1 November 2019
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 11 (3) , 83-88
Open AccessNonsuicidal self-injury in mentally ill patients: a clinical case
Nonsuicidal self-injuries (autotomy, self-inflicted destruction, self-mutilation) is a variant of autoaggression in a patient without the intent to take his/her own life. Patients with the consequences of self-injuries receive help from physicians of various specialties, who often cannot determine their motivation for autoaggressive actions, since it is associated with mental disorders. The paper presents data on phenomenology, some classifications and motivation of nonsuicidal self-injuries. Various mental disorders are noted to be the most common cause of autoaggressive behavior. The paper describes a clinical case of a female patient who has mutilated her face for a long time, hiding the cause of her autoaggressive action. A detailed clinical and psychopathological analysis of her medical history and mental status allowed for classifying hypochondriacal delirium within schizophrenia as a cause of self-mutilating actions. The motivation for this behavior was to fight against a pseudotumor, for which the patient suffered pain and prolonged suppurative processes on the skin of the face, without visiting physicians.